Europe’s Joint Clinical Assessment promises harmonization, but it introduces a new layer of strategic complexity that manufacturers must navigate at both EU and national levels.
Diane Cosset
Advertisement
Partner at Simon-Kucher, Paris.
Articles by Diane Cosset
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Eli Lilly Seeks Agreement with U.K. Government to Raise Prices for Medicines: Report
2
Eli Lilly and Insilico Enter $2.75 Billion Research and Licensing Agreement to Advance AI Drug Discovery
3
Pharmaceutical Executive Daily: Eli Lilly Presses U.K. Government to Raise NHS Drug Pricing
4
How Does MFN Pricing Work Within TrumpRx?
5